Hemostemix (CVE:HEM) Stock Price Down 11.8% – Should You Sell?

Hemostemix Inc. (CVE:HEM)’s stock price traded down 11.8% during mid-day trading on Tuesday . The stock traded as low as C$0.08 and last traded at C$0.08. 736,291 shares were traded during trading, an increase of 51% from the average session volume of 489,111 shares. The stock had previously closed at C$0.09.

Hemostemix Trading Down 5.9%

The business has a 50-day moving average of C$0.10 and a 200-day moving average of C$0.14. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a market cap of C$11.66 million, a price-to-earnings ratio of -2.33 and a beta of 0.20.

Insider Transactions at Hemostemix

In related news, Director Peter Alan Lacey purchased 200,000 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was bought at an average price of C$0.15 per share, for a total transaction of C$30,000.00. Company insiders own 10.43% of the company’s stock.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.